The partnership will use AI and data analytics to transform supply chain efficiency
SkyCell, the purpose-led technology company transforming the pharmaceutical supply chain, has partnered with lane risk assessment platform, Validaide to improve decision-making and enhance lane risk assessments for pharmaceutical companies.
The pharmaceutical industry loses approximately $35 billion annually due to failures in temperature-controlled logistics. The partnership aims to address these challenges by allowing companies to make data-driven routing decisions, streamline lane risk assessments, and accelerate lane approvals for critical shipments, ultimately helping pharmaceutical companies make better supply chain decisions.
The partnership will see SkyMind — SkyCell’s supply chain software platform — integrate with Validaide’s lane risk assessment and ground handling data, allowing pharma companies to make better decisions based on risk, cost and carbon emissions. SkyMind’s CO₂e software DECARBONIZE is based on the Massachusetts Institute of Technology (MIT) latest research and methodology. The DECARBONIZE software allows the comparison of one-way versus reusable packaging options, allowing companies to minimize their environmental impact while making informed decisions. With this collaboration, Validaide’s platform will be enhanced to make lane risk assessments and CO₂e comparison with different packaging at the same time.